Emergent BioSolutions Inc.EBSNYSE
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+111.9%
5Y CAGR+40.9%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+111.9%/yr
vs +29.6%/yr prior
5Y CAGR
+40.9%/yr
Recent acceleration
Acceleration
+82.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 1394.74% |
| Q3 2025 | -105.51% |
| Q2 2025 | 799.32% |
| Q1 2025 | 81.86% |
| Q4 2024 | -155.17% |
| Q3 2024 | 244.76% |
| Q2 2024 | 158.45% |
| Q1 2024 | -454.59% |
| Q4 2023 | -56.33% |
| Q3 2023 | 137.35% |
| Q2 2023 | 36.26% |
| Q1 2023 | -520.04% |
| Q4 2022 | 146.52% |
| Q3 2022 | -113.63% |
| Q2 2022 | 31.37% |
| Q1 2022 | -124.62% |
| Q4 2021 | 833.25% |
| Q3 2021 | 60.19% |
| Q2 2021 | -89.61% |
| Q1 2021 | -124.39% |
| Q4 2020 | 251.43% |
| Q3 2020 | -35.88% |
| Q2 2020 | 176.19% |
| Q1 2020 | -60.93% |
| Q4 2019 | 567.39% |
| Q3 2019 | 63.13% |
| Q2 2019 | -159.83% |
| Q1 2019 | 144.70% |
| Q4 2018 | -226.15% |
| Q3 2018 | 605.03% |
| Q2 2018 | 266.43% |
| Q1 2018 | -118.96% |
| Q4 2017 | 220.67% |
| Q3 2017 | -53.61% |
| Q2 2017 | 109.21% |
| Q1 2017 | 173.20% |
| Q4 2016 | -392.44% |
| Q3 2016 | 143.13% |
| Q2 2016 | -218.20% |
| Q1 2016 | 341.41% |